SATB2 and carcinosarcoma: SATB2 was positive in 83% of low‐grade endometrial stromal sarcomas, 40% of undifferentiated sarcomas, 13% of leiomyosarcomas, 14% of adenosarcomas, and 8% of carcinosarcomas [10].